Navigation Links
Virginia G. Piper Cancer Center vaccine study hopes to improve pancreatic cancer treatment
Date:6/13/2014

SCOTTSDALE, Ariz. June 12, 2014 Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

The Phase 2B clinical trial of CRS-207 and GVAX Pancreas vaccines is open at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen), where cancer patients are treated with promising new drugs.

Participants in the study, named ECLIPSE (Efficacy of Combination Listeria/GVAX Immunotherapy in the Pancreatic Cancer Setting), will be randomized so patients receive only the CRS-207 vaccine, or that vaccine combined with the GVAX Pancreas vaccine and low doses of cyclophosphamide. A third group of patients will receive a standard chemotherapy.

"This is a very innovative approach using immunotherapy to treat pancreatic cancer," explained Dr. Erkut Borazanci, M.D., M.S., medical oncologist and Drug Development Scholar at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and the study's lead investigator.

The CRS-207 vaccine is a weakened form of the bacteria, Listeria monocytogenes, that has been genetically modified to be safe for human use, while retaining its ability to stimulate the immune system. Specifically, CRS-207 has been engineered to stimulate an immune response against the tumor-associated antigen mesothelin, which is present at high levels on pancreatic cancer cells.

The GVAX vaccine is composed of genetically modified, inactivated pancreatic cancer cells that have been shown to stimulate the immune system's anticancer activity. The vaccine is given with a low-dose of a common cancer drug called cyclophosphamide to boost the effectiveness of the vaccine.

In a recently completed Phase 2A trial in 93 patients with advanced pancreatic cancer, survival was improved in patients who received the combination regimen of CRS-207, GVAX and cyclophosphamide (6.1 months), compared to 3.9 months for those who received only cyclophosphamide and GVAX. The immunotherapies were well-tolerated, with no serious treatment-related adverse side effects.

Virginia G. Piper Cancer Center Clinical Trials is among the first 11 centers in the United States participating in the study. The drug was developed by Aduro BioTech, Inc., a clinical-stage immunotherapy company located in Berkeley, Calif. A total of 240 patients are expected to be treated at more than 20 clinical trial sites in North America.

"If this study is successful, we hope that this form of immunotherapy will become widely available across the country to treat patients with advanced pancreatic cancer," added Dr. Borazanci.

Pancreatic cancer is difficult to treat and is the fourth leading cause of cancer-related death in the U.S. Tumors may grow in the pancreas without any early symptoms, which means that the disease is often in an advanced stage when it is diagnosed, and survival remains poor.

Virginia G. Piper Cancer Center Clinical Trials is known worldwide for its expertise in studying new treatments for pancreatic cancer.

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at clinicaltrials@shc.org. Additional information is available at http://www.clinicaltrials.gov (NCT02004262).


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Virginia Tech updates football helmet ratings, 5 new helmets meet 5-star mark
2. Virginia Tech scientists out for blood when it comes to stopping malaria
3. Class Action Lawsuit Filed on Behalf of West Virginia Residents Affected by Recent Chemical Spill
4. West Virginia Business Owners Represented in Class Action Lawsuit over Elk River Chemical Spill
5. The Bell Law Firm Filing Class Action Complaints on Behalf of West Virginia Contaminated Water Victims
6. Virginia Tech researchers find novice teen drivers easily fall into distraction, accidents
7. The Science Museum of Virginia Receives Largest Private Gift in Its History
8. Audiologists at Virginia Hearing Consultants in Norfolk VA Share Warnings about Everyday Ototoxic Drugs
9. Audiologists at Maico Audiological Services in Newport News Virginia Advise Consumers about Drugs that Lead to Hearing Loss
10. Northern Virginia Real Estate Company Pasquali Realty Group Suggests These New Year’s Resolutions For Homeowners
11. Northern Virginia Real Estate Company Pasquali Realty Group Announces Prices Up in November
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology: